BioWorld Asia

March 26, 2003

British Biotech, RiboTargets Plan Merger Despite Reduced Valuation

LONDON - After two years of searching, British Biotech plc finally landed a merger partner, privately held RiboTargets Holdings plc, a structure-based drug discovery specialist that brings £19 million (US$30 million) to add to British Biotech's £32 million cash pile. (BioWorld International) Read More

Cellzome Lands EUR30M Financing For Programs In Drug Discovery

Study Elucidates Neural Networks Of The Spinal Cord In Mammals

Ingenium, Elan Collaborate To Develop Drugs To Manage Pain

Gamida-Cell, Teva Enter Deal To Develop Stem Cell Product

Biovitrum Moves Diabetes Drug Into Controlled Phase II Study

Basilea Planning Phase III Trial Of Lead Drug For Hand Dermatitis

Vernalis Results, Cash Shortfall Come As Surprise To Investors

Celltech's Acquisition Of Stake In OGS Puts Pressure On CAT

Genopole Now Boasts 42 Biotech Companies And 23 Laboratories

EU Leaders Continue To Express Support For Biotech - In Principle

Serono Demonstrates Efficacy Of Raptiva Over The Long Term

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 13, 2026.

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 10, 2026

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...